1. Academic Validation
  2. Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication

Acyclic nucleoside thiophosphonates as potent inhibitors of HIV and HBV replication

  • Eur J Med Chem. 2011 Sep;46(9):4281-8. doi: 10.1016/j.ejmech.2011.06.034.
Karine Barral 1 Clément Weck Nadine Payrot Loic Roux Céline Durafour Fabien Zoulim Johan Neyts Jan Balzarini Bruno Canard Stéphane Priet Karine Alvarez
Affiliations

Affiliation

  • 1 Laboratoire d'Architecture et Fonction des Macromolécules Biologiques, UMR CNRS 6098, Equipe Réplicases Virales: Structure, Mécanisme, et Drug-design, Universités Aix-Marseille I et II, Parc scientifique de Luminy, 163 av de Luminy, 13288 Marseille Cedex 9, France.
Abstract

9-[2-(Thiophosphonomethoxy)ethyl]adenine 3 and (R)-9-[2-(Thiophosphonomethoxy)propyl]adenine 4 were synthesized as the first thiophosphonate nucleosides bearing a sulfur atom at the α-position of the acyclic nucleoside phosphonates PMEA and PMPA. Thiophosphonates S-PMEA 3 and S-PMPA 4 were evaluated for in vitro activity against HIV-1 (subtypes A to G), HIV-2 and HBV-infected cells, and found to exhibit potent antiretroviral activity. We showed that their diphosphate forms S-PMEApp 5 and S-PMPApp 6 are readily incorporated by wild-type (WT) HIV-1 RT into DNA and act as DNA chain terminators. Compounds 3 and 4 were evaluated for in vitro activity against a broad panel of DNA and RNA viruses and displayed beside HIV a moderate activity against herpes simplex virus and vaccinia viruses. In order to measure enzymatic stabilities of the target derivatives 3 and 4, kinetic data and decomposition pathways were studied at 37 °C in several media.

Figures